Albumin

Global Plasma Fractionation Market Valued at $5 Billion in 2023, Expected to Surge with 10% CAGR by 2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Pharmaceutical, Government, Partnership, COVID-19, Pharmacy, Prevalence, CSL, Therapy, Primary immunodeficiency, Ageing, Protease, Rare, Takeda Pharmaceutical Company, Type, Antibody, Collection, Bio Products Laboratory, Growth, Takeda, BPL, Patient, Albumin, Blood product, Rare-earth element, Pharmaceutical industry, Sintering, Grifols, Plasma

The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.

Key Points: 
  • The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.
  • Plasma Collection Centers in the US: Currently, the United States is home to approximately 80% of the world's plasma donation centers.
  • The country supplies over 70% of the plasma used in the manufacturing of plasma-derived therapies through the process of plasma fractionation.
  • Importance of Plasma Fractionation: Plasma fractionation is a critical process for separating and purifying key blood plasma components, including immunoglobulins, albumins, anticoagulant factors, and protease inhibitors.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, May 10, 2023
Phibro, RBD, Marketing, Public, Enzyme, Biomedical Advanced Research and Development Authority, Fungus, Influenza, Science, Development, Pandemic, Protein, COVID-19 vaccine, Patent, WNV, Rubic Ghasemi-Nobakht, TBEV, Antigen, University of California, Davis, Albumin, Therapy, Fermentation, Research, Infection, Gene expression, Consultant, RVFV, CGMP, Manuscript, Recombinant, Growth, FDA, BARDA, ACE2, Safety, D, Vaccine, DNA, COVID-19, Antibody, CSR, Government, Animal, UC, Webcast, Food, Omicron, Education, SARS-CoV-2, Clinical trial, CHO, Sale, NIIMBL, Health, Pharmaceutical industry, Financial adviser, Cryptocurrency, Fine chemical, Rare-earth element, Video game, EU, African, C1, Dyadic

Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.

Key Points: 
  • Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.
  • In the first quarter of 2023, the Company entered into a new research collaboration with a biotech company for a fully funded proof-of-concept project to express an enzyme for pharmaceutical applications.
  • G&A Expenses: General and administrative expenses for the quarter ended March 31, 2023, decreased by 10.6% to approximately $1,480,000 compared to $1,656,000 for the quarter ended March 31, 2022.
  • Other Income: Other income for the quarter ended March 31, 2023 was from the sale of the equity interest in Alphazyme, LLC.

The Worldwide Albumin Industry is Expected to Reach $8.9 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 20, 2022
Health, Pharmaceutical, People, Serum albumin, Antibody, Awareness, Degenerative disease, Fatality, Acute respiratory distress syndrome, Acute liver failure, Trauma, Health, Hypovolemia, Adoption, CAGR, Bleeding, Drug development, Chronic liver disease, Therapy, Growth, Shock, Burns, Prevalence, Albumin, Hypoalbuminemia

The "Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021--2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021--2030" report has been added to ResearchAndMarkets.com's offering.
  • The Albumin market was valued at $4,813.5 million in 2020, and is estimated to reach $8,956.07 million by 2030, growing at a CAGR of 6.4% from 2021 to 2030.
  • Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used.
  • This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the albumin market.

Insights on the Plasma Protein Therapeutics Global Market to 2027 - Increasing Research and Development Activity Related to the Plasma Protein Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 5, 2022
Health, Biotechnology, COVID-19, Decision-making, Investment, Strategic management, Coagulation, Blood, Compound annual growth rate, Business Growth Fund, Value, USD, Use, Albumin, Certification, Market share analysis, R, CAGR, Technology, Growth, Acquisition, Customer support, Retail, Medical device, Fine chemical, Blood product

What are the inhibiting factors and impact of COVID-19 shaping the Global Plasma Protein Therapeutics Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Plasma Protein Therapeutics Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Plasma Protein Therapeutics Market?
  • What is the market share of the leading vendors in the Global Plasma Protein Therapeutics Market?
  • What modes and strategic moves are considered suitable for entering the Global Plasma Protein Therapeutics Market?

Worldwide Plasma Protein Therapeutics Industry to 2027 - Key Drivers, Restraints and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 14, 2021
Health, Biotechnology, Haemophilia, Chickenpox, Patient, Technology, Diagnosis, A&B, Blood, Immunity, Immunodeficiency, Protein, Asia, Therapy, Hereditary angioedema, Tetanus, Rabies, Cirrhosis, VIII, Coagulation, Albumin, Hepatitis, Autoimmunity, Quality of life, Lists of diseases, Vaccine, Generic drug

To treat life-threatening, chronic, and genetic diseases, plasma protein therapeutics are used, consisting of biological medicines, either infused or injected.

Key Points: 
  • To treat life-threatening, chronic, and genetic diseases, plasma protein therapeutics are used, consisting of biological medicines, either infused or injected.
  • The key propellant factor for the plasma protein therapeutics market growth is the rising advents of new plasma-derived therapies.
  • As in the plasma protein therapeutics market for application, the applications of the plasma protein therapeutics include Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic, Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and Others.
  • Quality and advancements in plasma therapeutics have been the favorable drivers of the global plasma protein therapeutics market to enhance patients' quality of life and assure donor safety.

Global Human Albumin Market Insights (2021 to 2026) - Key Analysis and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021
Health, Biotechnology, Albumin, CAGR, Pet

The "Human Albumin Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Albumin Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering.
  • This report describes the global market size of Human Albumin from 2016 to 2020 and its CAGR from 2016 to 2020, and also forecasts its market size to the end of 2026 and its CAGR from 2021 to 2026.
  • For the geography segment, regional supply, demand, major players, price is presented from 2016 to 2026.
  • This report covers the following regions:

New Studies Demonstrate Role of High-Flux Dialyzers in Managing Albumin

Retrieved on: 
Thursday, July 29, 2021
Blood proteins, Branches of biology, Medicine, Hypoalbuminemia, Anatomy, Serum albumin, Serum, Albumin, Hemodialysis

This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.

Key Points: 
  • This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.
  • "This study further demonstrates that high-flux dialyzers can play a role in increasing albumin levels, and especially for those patients with higher body mass index and inflammation."
  • "These results further reinforce the important role that high-flux dialyzers like Optiflux can play in helping address the potential dangers of low serum albumin levels."
  • The authors note that "excessive" loss of albumin is a theoretical concern with the chronic use of increasingly permeable dialyzers.

DGAP-News: Biotest AG: Annual General Meeting approves dividend distribution

Retrieved on: 
Tuesday, May 11, 2021
Financial markets, Financial economics, Corporate finance, Equity securities, Stock market, Preferred stock, Dividend, Share, Albumin

At the second ordinary, virtual Annual General Meeting on 11 May 2021, the shareholders of Biotest AG resolved to distribute a dividend.

Key Points: 
  • At the second ordinary, virtual Annual General Meeting on 11 May 2021, the shareholders of Biotest AG resolved to distribute a dividend.
  • The resolution on the appropriation of the net profit was passed with 99.96% approval for a distribution of \xe2\x82\xac 0.04 per preference share.
  • Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.\n'

Investigation Report on China's Human Serum Albumin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 10, 2021
Surgery, Health, Blood proteins, Human serum albumin, Serum albumin, Albumin, Serum, HSA

b'The "Investigation Report on China\'s Human Serum Albumin Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this market report, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020.\nHuman Serum Albumin (HSA) is made of plasma proteins from human blood, which is mainly used to replace blood volume loss resulting from trauma such as a severe burn or an injury that causes blood loss.

Key Points: 
  • b'The "Investigation Report on China\'s Human Serum Albumin Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this market report, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020.\nHuman Serum Albumin (HSA) is made of plasma proteins from human blood, which is mainly used to replace blood volume loss resulting from trauma such as a severe burn or an injury that causes blood loss.
  • Currently, there are over 30 manufacturers in the Chinese HSA market.
  • The CAGR of the sales value of Human Serum Albumin in China is 9.3% from 2016 to 2020.
  • The analyst analyzes that as the epidemic situation has been improved and the hospitals resume their operation, sales of HSA will have a recovery growth from 2021 to 2025.\n2 Sales of Human Serum Albumin in China, 2016-2020\n2.3 Sales of Human Serum Albumin by Dosage Form in China, 2016-2020\n3 Analysis of Major Human Serum Albumin Manufacturers in China, 2016-2020\n3.6 Shandong Taibang Biological Products Co., Ltd.\n4 Prices of Human Serum Albumin for Different Manufacturers in China, 2020-2021\n'